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1. Introduction
The mass spectrometry (MS) is a technology enabling the measurement and 
analysis of multiple analytes with very high sensitivity and selectivity. The MS “use 
for purpose” includes the analysis of proteins and their modifications using either 
the top-down or the bottom-up approach, the analysis of multiple parameters 
for toxicology research, targeted analysis of active pharmaceutical compounds in 
patients’ samples.
Recent years has brought a significant improvement of technology for ion-trap, 
the time-of-fligt, and triple quadrupole instruments resulting with a surge in 
applications for the medical, biological, and inorganic field. One of the greatest 
challenges for the MS was how to solve the problem of the insufficient ion transfer 
from the ionization source through different mass filters and to the detector. This 
challenge can be considered essentially solved due to changes in the design of 
ion-sources and subsequent mass filters such as ion funnels of different design, 
which enabled hugely improved ion focusing and ion transfer. However, there is still 
enough space to further improve the design of the interface to enable handling of 
larger ion currents generated by more powerful and more intense electrospray (ESI) 
ion sources. That would make bulky, expensive, and complex pumping systems 
obsolete. Actually, the greatest challenge of improving the MS is the ionization step, 
particularly when MS is used in combination with the liquid chromatography (LC). 
The combination of LC and MS (LC–MS) has advanced to the main workhorse in 
many laboratories, especially in biotechnology and medical laboratories. Since the 
low LC flow rate significantly increases the efficiency, the sensitivity, and the stabil-
ity of the ESI, the use of separation columns with small inner diameters is recom-
mended for the hyphenation of the two technologies. In cases with very low flow 
rates, e.g. 5–50 nl/min, a complete ionization of a substance can be achieved. On 
the other side, the use of such a low flow rates causes problems with flow’s stability, 
reproducible flow gradient mixing, and stable ESI performance.
2. Clinical laboratory and mass spectrometry
The laboratory medicine along with medical imaging procedures is one of 
the pillars of the modern diagnostics. The laboratory medicine has significantly 
benefitted from technical and technological development of analytical chemistry, 
miniaturization of instruments, and optimization of analytical methods.
Colorimeter and spectromphoter were the first modern analytical instruments 
to be used in a clinical laboratory. Since the time of their introduction, the art of 
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performing analyses and tests has significantly changed. In the 1950’s additional 
developments were made and, in 1957 and 1959, respectively, the autoanalyzer, 
which is the precursor to the modern analytical systems, and the first RIA (immu-
noassay) for analysis of insulin were introduced. The introduction of RIA, which 
is still widely used, for insulin has significantly improved and changed the art of 
measuring a large of compounds.
The introduction of the mass spectrometry (MS) into the clinical laboratory 
had had the same revolutionary impact as the previously mentioned methods. A 
brief search for “mass spectrometry” and “clinical” from 1950 until 1970 results 
with only 9 publications! During the next 20 years, until 1990, the number of 
publications referring to the use of MS for different analyses in clinical laboratory 
jumped to 798! From the early 1990’s until today, the steep rise of MS methods and 
approaches for analyses in clinical laboratory has steeply raised with more than 
5000 publications from January 1st, 2020 – February 1st, 2021.
The significant rise in use of different MS approaches for clinical analyses cor-
relates with improvements in ionization technologies, miniaturization of separation 
systems, notably of chromatographic systems (HPLC) [1], the significant and excit-
ing improvements in sample preparation even of a single cell [2], and bioinformatic 
analysis. The mass spectrometry is applied for both “classical” clinical laboratory 
analyses and for analyzing samples for personalized and precision medicine. 
Undoubtly, the approaches and methods describe in current book are only a small 
part of possible applications.
In clinical laboratories, the analysis of clinical samples and monitoring levels of 
active compounds and their metabolites in e.g. patients’ blood and urine samples 
are the main application fields. It is possible to perform specific detection of target 
analytes by applying MRM/SRM (multiple-reaction monitoring/selected-reaction 
monitoring) or SIM (single-ion monitoring) thus significantly enhancing the 
selectivity and sensitivity of the analytical method and provide targeted and highly 
specific analytical approach.
3. Separation approaches
Analytes of interest in complex biological samples must be separated prior 
to mass spectrometric detection and analysis and chromatography is the most 
widely used separation method for biological samples prior to MS. A number of 
Companies, e.g. Chromsystems (https://www.chromsystems.com/), ThermoFisher 
Scientific (https://www.thermofisher.com/at/en/home/clinical/diagnostic-testing/
clinical-chemistry-drug-toxicology-testing/therapeutic-drug-monitoring.html), 
Biocrates (https://biocrates.com/) or BioRad (www.bio-rad.com) developed 
analytical systems for a broad range of analyses of important clinical parameters. 
Integrated HPLC–MS clinical systems were also developed but they never really 
did find broad acceptance. Sciex introduced the Topaz® system (https://www.
businesswire.com/news/home/20170731005050/en/First-Fully-Integrated-LC-
MS-System-for-Clinical-Diagnostics-Announce-by-SCIEX) and Thermo Fisher 
introduced the Cascadion SM lab analyzer (https://www.labmedica.com/aacc-2017/
articles/294770271/worlds-first-fully-integrated-lc-ms-ms-clinical-analyzer-un-
veiled.html) in order to lower the barriers of many laboratories to adopt LC–MS.
The hyphenation of chromatography and mass spectrometry has its primary 
values in relatively fast detection and analysis of multiple analytes in a single 
sample with high sensitivity and high selectivity - the key challenge and require-
ment to detect and quantify low-concentration analytes. Currently, the most widely 
used separation columns for the HPLC–MS in a clinical laboratory have an inner 
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diameter of 2 mm. The quality of electrospray is highly dependable on separation 
conditions, i.e. mobile phase, presence or absence of salts, flow speed, column’s 
inner diameter, etc. In proteomics, the use of separation columns with 50 μm or 
75 μm ID is state-of-the-art; however, the columns operated at a low flow rate of 
several hundreds of nanoliters/minute are still rare in clinical analysis although 
they can provide a significant increase of sensitivity. Currently, the use of nanoflow 
separation still cannot cope with the demand for high sample throughput and 
robustness in clinical applications. Currently, the closest compromise between 
sensitivity and throughput is the use of the microbore and the capillary columns of 
300 μm – 500 μm and 1 mm – 2 mm inner diameter.
A new and exciting application of mass spectrometry in the clinical environment is 
the use of “live-MS” during surgical operations. Further development of this approach 
will revolutionize the diagnostics and help surgeons in extracting e.g. tumors with 
higher accuracy and better prognosis for the patient following the surgery [3–5].
In addition of analyzing small molecules in a targeted approach, the mass 
spectrometry can be applied in a clinical laboratory for a more widely screening 
approaches, e.g. screening of the human metabolome. The metabolome shed a light 
on our biological life story, reviling changes and processes that happened due to our 
genetics and due to the influence of the environment and the lifestyle. The measure-
ment, detection, and analysis of metabolites is a step towards profiling an individu-
als’ metabolic profile at any given time. That information can help understanding 
and, eventually, predicting the impact of environmental factors on the health. 
Therefore, metabolomics, in combination with other omics methods is a potent 
addition to developing personalized medical approaches.
A number of analytical methods for mass spectrometry in clinical laboratories 
were developed during the recent past, and the development gains additional 
momentum as the CoVID-19 pandemics holds the mankind in grip and methods for 
fast HPLC–MS have been developed and applied [6–15].
4. Clinical proteomics
The use of MS technology for measurement and analysis of clinically important 
peptides and protein biomarkers will definitively increase with further improving 
MS technology. It is clear that personalized medicine will become the major field of 
further development of targeted therapy and MS will be one of the major players 
in identifying both therapeutically targets and therapeutical agents. It is with great 
certainty that MS applications for evaluation of protein and peptide-based, or even 
the mRNA-based therapeutics, will play a crucial part for the quality control of the 
therapeutics, evaluating drug efficacy, or investigating therapeutic response.
Another issue is the miniaturization of MS and LC–MS systems that can be 
used portable systems or be applied in smaller field-laboratories. Certain advances 
were already achieved on developing such devises [16–23] that are being used in a 
number of analyses.
To conclude, mass spectrometry is a powerful analytical technology that still 
has not developed her full potential for use in clinical laboratory although its’ use 
is growing. Different mass spectrometry-based devices have been approved for 
screening newborns, identifying microbes and fungus in cultures of human cells 
or for detecting measuring the concentrations of drugs (therapeutic and illicit) 
in body fluids. The development of large and integrated HPLC–MS systems for 
detecting and measuring peptides or proteins in clinical laboratories is still waiting 
to happen but mass spectrometry has already gained access to all areas of medical 
research and diagnostics.
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